Elcin Barker Ergun, Menarini Group CEO
Amid Roche and Sanofi's oral SERD setbacks, Menarini gets speedy review at FDA
Menarini and Radius Health are getting a speedy review at the FDA for their oral SERD breast cancer drug months after the field opened up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
